LC
SAGE

Lindbrook Capital’s Sage Therapeutics SAGE Stock Holding History

Lindbrook Capital’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$533 Buy
+67
New +$491 ﹤0.01% 2611
2024
Q3 		– Sell
-459
Closed -$4.99K – 2899
2024
Q2 		$4.99K Buy
459
+261
+132% +$3.34K ﹤0.01% 1993
2024
Q1 		$3.71K Hold
198
– – ﹤0.01% 2030
2023
Q4 		$4.29K Sell
198
-80
-29% -$1.58K ﹤0.01% 1963
2023
Q3 		$5.72K Buy
278
+214
+334% +$6.18K ﹤0.01% 1705
2023
Q2 		$3.01K Buy
64
+12
+23% +$597 ﹤0.01% 1999
2023
Q1 		$2.18K Sell
52
-4
-7% -$172 ﹤0.01% 2207
2022
Q4 		$2.14K Sell
56
-177
-76% -$6.76K ﹤0.01% 2204
2022
Q3 		$9K Buy
+233
New +$9.01K ﹤0.01% 1387
2022
Q2 		– Sell
-73
Closed -$2K – 2733
2022
Q1 		$2K Buy
+73
New +$2.74K ﹤0.01% 2073
2021
Q4 		– Sell
-55
Closed -$2K – 2189
2021
Q3 		$2K Buy
55
+15
+38% +$688 ﹤0.01% 1597
2021
Q2 		$2K Sell
40
-12
-23% -$848 ﹤0.01% 1637
2021
Q1 		$4K Hold
52
– – ﹤0.01% 1354
2020
Q4 		$4K Hold
52
– – ﹤0.01% 1277
2020
Q3 		$3K Hold
52
– – ﹤0.01% 1308
2020
Q2 		$2K Buy
+52
New +$1.89K ﹤0.01% 1430

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

Lindbrook Capital's SAGE Position: Q1 2025 in Review

Lindbrook Capital opened a new position in Sage Therapeutics (SAGE) in Q1 2025: 67 shares worth $533. The stake represents ﹤0.01% of the portfolio and ranks #2611 among its holdings. This is a return to the name: Lindbrook Capital previously reported a position in SAGE as recently as Q2 2024.

Lindbrook Capital first reported a position in SAGE in Q2 2020 and has held it in 16 quarters since. The position peaked at $9K in Q3 2022. 198 funds tracked by Wall St. Rank hold SAGE as of Q1 2025.

  • Lindbrook Capital held 67 shares of Sage Therapeutics worth $533 as of Q1 2025.
  • Sage Therapeutics was a new Lindbrook Capital position in Q1 2025.
  • Sage Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2611 holding.
  • Lindbrook Capital first reported a position in Sage Therapeutics in Q2 2020 and has held it in 16 quarters since.
  • Lindbrook Capital's Sage Therapeutics position peaked at $9K in Q3 2022.
  • 198 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.